Indonesia healthcare market has shown a positive incline during 2012-2017 but with respect to the expanding population of Indonesia, the market is still underserved especially in the underdeveloped and rural areas as of 2017. People across Indonesia are facing several health care issues due to sedentary lifestyle and fast food consumption habits, such as obesity, diabetes, and other cardiovascular diseases, which are demanding for technologically advanced healthcare infrastructure. The Indonesia healthcare market has increased on the account of increasing healthcare facilities, innovation in pharmaceutical manufacturers and clinical laboratory services and expansion of pharmacy retail chains across the country. The market has witnessed enhancing innovation in nutritional health segment, biopharmaceuticals and specialty pharmaceutical products.
Hospitals in the country contributed to the maximum share of overall healthcare market as of 2016. Over ~% of the market revenues were generated from the hospitals segment followed by the pharmaceutical market with ~% in 2017.
Indonesia Healthcare market revenue has increased from USD ~ billion in 2012 to USD ~ billion in 2017 primarily due to rising prevalence of non-communicable and lifestyle diseases including diabetes, asthma and heart disorders. The industry has undergone various deregulation programs which has encouraged foreign investment in the industry. Furthermore, increase in demand for generic medicines has led the major players in the industry to expand their production capabilities.
Indonesia Clinical Laboratory Market is in the growing stage. The market has grown at a CAGR of ~% during 2012 to 2017 with revenue estimated at USD ~ billion in 2017. The industry has witnessed expansion of private laboratory chains and use of advanced technology in order to provide high quality laboratory services. With the implementation of JKN, the demand for laboratory services has further increased. The public hospitals mostly perform routine test while the esoteric tests are outsourced to the private clinical laboratories. Due to growing awareness amongst people about healthy living, private and public laboratories have witnessed an increase in walk in patients asking for routine checkups which is funded out of the patient’s pocket. Further, the major private laboratory chains have expanded their operations in terms of capacity and geographic presence. The six major private laboratories occupying ~% of the revenue share of Indonesia Private independent labs in 2016 are Prodia, Kimia Farma, Pramita, Cito, Parahita and BioMedika.
The public clinical labs have accounted for ~% of the revenue share in Indonesia clinical laboratory market in 2017. Private hospital labs have accounted for ~% in 2017 and private independent labs with ~% of the overall market. The laboratory chains have been the leading market players in Indonesia in 2016 with ~% of revenue in the overall private independent laboratory market in 2016. Single independent labs have contributed to their lower revenue share of ~% due to their restricted geographic presence.
Doctor Referrals have accounted for the largest share of ~% of the tests in Indonesia Private independent laboratory market in 2016. With growing awareness about chronic diseases and their treatment procedure increasing number of Indonesians have taken charge of their own health. This has led to an increase in number of walk-ins at medical laboratories which has registered ~% of the tests. This is followed by corporate clients with ~% of the tests and external referrals with ~% of the total tests in 2016
Routine tests have accounted for ~% of the revenue in Indonesia Private independent laboratory market in 2016. This is followed by esoteric tests with ~% and non laboratory tests with ~% of the overall private independent laboratory market. Esoteric tests require a professional approach from highly-skilled technical personnel, often utilize more sophisticated technology, equipment or materials and are generally ordered less frequently than routine tests. Generally, margins for esoteric tests are higher as compared to routine tests.
Java, Sumatra, Bali, Jakarta and Palembang have together accounted for ~% of the revenue in the overall private laboratory market in 2016. This is driven by high rate of urbanization and more affluent population, which has created greater demand for private clinical laboratory testing services. Underdeveloped cities such as Sulawesi, Maluku and Kalimantan have together accounted for ~% of the revenue in 2016.
The UHC scheme has increased the demand for basic and specialized testing. Since public clinical labs are not equipped with the technology for specialized testing, such tests have been outsourced to private independent laboratories. Rising major illness of NCDs and CDs has driven the demand for cardiovascular tests, tumor markers, metabolic tests, malaria and TB tests. There has been an increase in middle to high income earners seeking preventive health check-ups. Health check-ups are driven by walk-in patients and corporate clients who have together contributed up to 50% of the total test volume of a private independent laboratory. In addition to this, it is expected that the number of people taking health check-ups to grow by 2.2% on a yearly basis as more emphasis is given to the promotion of preventive health checkups. Major laboratory chains such as Cito, Pramita and Prodia have hence introduced health check up packages for male, female, children, adolescents, and old age people. Further, there are packages for different diseases such as cancer, diabetes, cardiac, fertility and others. The market has witnessed introduction of wide range of tests from routine tests to more specialized tests, including genomic platform with multiplexing capabilities able to support different classes of patients with precise diagnosis and speed up treatment consultation.
The private independent clinical laboratory market is organized and is composed of both chain laboratories and stand-alone laboratories. The chain laboratories are the leading market players in Indonesia. The 6 major players in the industry are Prodia, Kimia Farma, Pramita, Cito, BioMedika and Parahita. They have together accounted for 71.2% of the revenue share in private independent laboratory market in 2017. The major players compete on distribution network, product portfolio, advertising, technology, Prices and services
The clinical laboratory market is expected to reach USD 3.2 billion by 2022 growing at a CAGR of 11.5%. The major private independent laboratories chains are expected to undergo geographic expansion beyond key cities into underdeveloped areas. It is also expected that the implementation of JKN will increase the demand for laboratory services. This will lead the public hospitals to refer samples to private independent laboratories for clinical testing, resulting in the growth of external referrals for private independent laboratories. Further, the industry will witness a rising trend towards precision medicine also known as personalized medicine. Further, the market for rapid tests will grow at a CAGR of 13% between 2016 and 2021 in Indonesia. The growth will be driven by factors such as increasing rate of infectious diseases such as dengue, malaria, hepatitis, and HIV, the government’s healthcare initiatives, and product advancements and innovations by rapid test manufacturers
For more information on the research report, refer to below link:
Related Reports by Ken Research
Ankur Gupta, Head Marketing & Communications